Ido Laish
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ido Laish has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Guy Rosner
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel
1 shared publication - Hana Strul
Tel Aviv Medical Center, Department of Gastroenterology, Tel Aviv 6423906, Israel
1 shared publication - Nathan Gluck
Faculty of Medical and Health Sciences, Tel-Aviv University, Tel-Aviv, Israel
1 shared publication - Ophir Gilad
Tel Aviv Medical Center, Department of Gastroenterology, Tel Aviv 6423906, Israel
1 shared publication - Revital Kariv
Department of Gastroenterology, Tel Aviv Medical Center, Tel Aviv 6423906, Israel
1 shared publication - Yael Petel-Galil
Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
1 shared publication
Latest Publications
- Open Access
- 31 August 2022
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (10) , e00527
Adenomatous Polyposis Phenotype in BMPR1A and SMAD4 Variant Carriers
INTRODUCTION: Variants in SMAD4 or BMPR1A cause juvenile polyposis syndrome, a rare autosomal dominant condition characterized by multiple gastrointestinal hamartomatous polyps. A phenotype of attenuated adenomatous polyposis without hamartomatous polyps is rare. METHODS: We describe a retrospective cohort of individuals with SMAD4 or BMPR1A heterozygous germline variants, having ≥10 cumulative colorectal adenomas and/or colorectal cancer without hamartomatous polyps. All individuals had multigene panel and duplication/deletion analysis to exclude other genetic syndromes. RESULTS: The study cohort included 8 individuals. The pathogenic potential of the variants was analyzed. Variants detected included 4 missense variants, 1 nonsense variant, 1 splice site variant, and 2 genomic deletions. Features of pathogenicity were present in most variants, and cosegregation of the variant with polyposis or colorectal cancer was obtained in 7 of the 8 families. Three of 8 individuals had colorectal cancer (age less than 50 years) in addition to the polyposis phenotype. Two individuals had extraintestinal neoplasms (pancreas and ampulla of Vater). DISCUSSION: The clinical phenotype of SMAD4 and BMPR1A variants may infrequently extend beyond the classical juvenile polyposis syndrome phenotype. Applying multigene panel analysis of hereditary cancer-related genes in individuals with unexplained polyposis can provide syndrome-based clinical surveillance for carriers and their family members.
- 31 August 2022
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 13 (10) , e00527
Open AccessAdenomatous Polyposis Phenotype in BMPR1A and SMAD4 Variant Carriers
INTRODUCTION: Variants in SMAD4 or BMPR1A cause juvenile polyposis syndrome, a rare autosomal dominant condition characterized by multiple gastrointestinal hamartomatous polyps. A phenotype of attenuated adenomatous polyposis without hamartomatous polyps is rare. METHODS: We describe a retrospective cohort of individuals with SMAD4 or BMPR1A heterozygous germline variants, having ≥10 cumulative colorectal adenomas and/or colorectal cancer without hamartomatous polyps. All individuals had multigene panel and duplication/deletion analysis to exclude other genetic syndromes. RESULTS: The study cohort included 8 individuals. The pathogenic potential of the variants was analyzed. Variants detected included 4 missense variants, 1 nonsense variant, 1 splice site variant, and 2 genomic deletions. Features of pathogenicity were present in most variants, and cosegregation of the variant with polyposis or colorectal cancer was obtained in 7 of the 8 families. Three of 8 individuals had colorectal cancer (age less than 50 years) in addition to the polyposis phenotype. Two individuals had extraintestinal neoplasms (pancreas and ampulla of Vater). DISCUSSION: The clinical phenotype of SMAD4 and BMPR1A variants may infrequently extend beyond the classical juvenile polyposis syndrome phenotype. Applying multigene panel analysis of hereditary cancer-related genes in individuals with unexplained polyposis can provide syndrome-based clinical surveillance for carriers and their family members.